Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All.
Sign Up to like & getrecommendations! Published in 2018 at "Advances in experimental medicine and biology"
DOI: 10.1007/978-3-030-02771-1_8
Abstract: The development of monoclonal antibodies (mAbs) cetuximab and panitumumab, which target the transmembrane protein epidermal growth factor receptor (EGFR), mark a major step forward in the treatment of metastatic colorectal cancer (mCRC). However, this therapeutic… read more here.
Keywords: metastatic colorectal; colorectal cancer; anti egfr; egfr therapy ... See more keywords
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-020-03509-x
Abstract: To determine the efficacy and safety data of aflibercept + FOLFIRI in wt RAS mCRC patients after progression to standard chemotherapy + anti-EGFR treatment. Retrospective, observational study in real life conducted in wt RAS mCRC patients treated with FOLFIRI-aflibercept… read more here.
Keywords: first line; treatment; anti egfr; ras mcrc ... See more keywords
Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale
Sign Up to like & getrecommendations! Published in 2019 at "Advances in Therapy"
DOI: 10.1007/s12325-019-00949-y
Abstract: KRAS (Kirsten rat sarcoma viral oncogene) or BRAF (v-raf murine sarcoma viral oncogene homolog B1) constitutive activation leads to anti-EGFR (epidermal growth factor receptor) therapy resistance of metastatic colorectal cancer patients. In this article we… read more here.
Keywords: metastatic colorectal; anti mek; colorectal cancer; anti egfr ... See more keywords
99mTc(CO)3+ labeled domain I/II-specific anti-EGFR (scFv)2 antibody fragment for imaging EGFR expression.
Sign Up to like & getrecommendations! Published in 2018 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2018.08.014
Abstract: Bifunctional chelators (BFCs) are covalently linked to biologically active targeting molecules and radiolabeled with radiometals. Technetium-99 m (99mTc) is the most widely used isotope in nuclear medicine because of its excellent physical properties. The objective of… read more here.
Keywords: antibody; scfv; anti egfr; dlo6 scfv ... See more keywords
Anti-EGFR Antibody Conjugation of Fucoidan-Coated Gold Nanorods as Novel Photothermal Ablation Agents for Cancer Therapy.
Sign Up to like & getrecommendations! Published in 2017 at "ACS applied materials & interfaces"
DOI: 10.1021/acsami.7b00294
Abstract: The development of novel photothermal ablation agents as cancer nanotheranostics has received a great deal of attention in recent decades. Biocompatible fucoidan (Fu) is used as the coating material for gold nanorods (AuNRs) and subsequently… read more here.
Keywords: ablation agents; novel photothermal; ablation; anti egfr ... See more keywords
Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery
Sign Up to like & getrecommendations! Published in 2017 at "Oncogene"
DOI: 10.1038/onc.2016.393
Abstract: The epidermal growth factor receptor (EGFR) is a transmembrane receptor with tyrosine kinase activity involved in regulation of cellular multiplication, survival, differentiation and metastasis. Our knowledge about function and complex management of these receptors has… read more here.
Keywords: extracellular region; factor receptor; growth factor; anti egfr ... See more keywords
The efficacy of anti-EGFR therapy in treating metastatic colorectal cancer differs between the middle/low rectum and the left-sided colon
Sign Up to like & getrecommendations! Published in 2021 at "British Journal of Cancer"
DOI: 10.1038/s41416-021-01470-2
Abstract: Background Clinically, metastatic rectal cancer has been considered a subset of left-sided colon cancer. However, heterogeneity has been proposed to exist between high and middle/low rectal cancers. We aimed to examine the efficacy of anti-epidermal… read more here.
Keywords: middle low; left sided; sided colon; anti egfr ... See more keywords
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies
Sign Up to like & getrecommendations! Published in 2018 at "Nature Communications"
DOI: 10.1038/s41467-018-06602-6
Abstract: Nowadays, personalized cancer therapy relies on small molecules, monoclonal antibodies, or antibody–drug conjugates (ADC). Many nanoparticle (NP)-based drug delivery systems are also actively investigated, but their advantage over ADCs has not been demonstrated yet. Here,… read more here.
Keywords: therapy; drug; anti egfr; avidin nucleic ... See more keywords
Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma
Sign Up to like & getrecommendations! Published in 2017 at "Scientific Reports"
DOI: 10.1038/s41598-017-06234-8
Abstract: Gallbladder carcinoma (GBC) is the most common malignant tumour in the biliary tract, but effective therapeutics are lacking. Based on our previous studies, miR-135a is a potential tool to inhibit GBC proliferation. In this study,… read more here.
Keywords: egfr cil; cil mir; anti egfr; gallbladder carcinoma ... See more keywords
Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2017.1356815
Abstract: ABSTRACT Introduction: Targeted agents alone or in combination with chemotherapy are current standard of treatment for metastatic colorectal cancer (mCRC). Panitumumab is a fully human monoclonal antibody which inhibits the epidermal growth factor receptor (EGFR).… read more here.
Keywords: metastatic colorectal; treatment; colorectal cancer; anti egfr ... See more keywords
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2020.1810573
Abstract: ABSTRACT Objectives Metastatic squamous cell carcinoma anal cancer (SCCA) is rare. Prospective data recommends front-line platinum doublet combinations and second-line anti-programmed death-1 therapy. Standard therapy beyond these treatments are currently unknown. We evaluated anti-EGFR monoclonal… read more here.
Keywords: cell carcinoma; scca; squamous cell; egfr monoclonal ... See more keywords